Navigation Links
ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
Date:8/27/2007

/p>

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(R), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera(TM) is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at http://www.immuneregen.com.

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging t
'/>"/>

SOURCE ImmuneRegen BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
2. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014  Aethlon Medical, Inc. (OTCQB: AEMD), ... address infectious disease, cancer and other life-threatening conditions, ... Agency (DARPA) has informed the Company that it ... year four of a five-year $5.9 million contract ... 2011 under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
(Date:9/22/2014)... BC , Sept. 22, 2014 /CNW/ - T-Bird ... company focused on developing premium quality medical marijuana products, ... Thunderbird Biomedical Inc. ("Thunderbird"), has signed a definitive lease ... Victoria , BC.  The facility has 28,966 square ... approximately 14,500 square feet of mezzanine space for a ...
(Date:9/22/2014)... CHICAGO, Ill. , Sept. 22, 2014 /PRNewswire/ ... data from several clinical studies evaluating potential new ... presented at the upcoming 2014 European Society of ... Madrid, Spain . Data being ... evaluating the safety and efficacy of veliparib (ABT-888), ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4
(Date:9/22/2014)... York (PRWEB) September 22, 2014 ... the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... a new report detailing the continued use of ... federal regulators that specifically discouraged these procedures. According ... that the potential cancer risks associated with power ...
(Date:9/22/2014)... Gray HealthDay Reporter MONDAY, ... woman wonders: What can I do to help ensure a ... as prescribed may play a role in reducing the risk ... The researchers found that mothers of children with autism were ... during pregnancy than those whose children seem to be developing ...
(Date:9/22/2014)... In a continued effort to support ... is launching an awareness campaign inspired by the ice ... aims to raise awareness and funds for the cause. ... in the air and trying to catch it while ... a nominee does not complete the challenge within 24 ...
(Date:9/22/2014)... Ind. Researchers have developed a chip capable ... use the new system to test the effectiveness ... new system, called a tumor-microenvironment-on-chip (T-MOC) device, will ... tumors and the barriers that prevent the targeted ... Purdue University associate professor of mechanical engineering., Researchers ...
(Date:9/22/2014)... 22, 2014 The New York Group ... Surgery at the Icahn School of Medicine at Mount ... Group for Plastic Surgery gives residents of New York ... team of world-renowned plastic surgeons performing innovative reconstructive and ... MD, who led NYGPS, was named the Director of ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:New chip promising for tumor-targeting research 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... be appointed for Scotland for coordinating efforts when an epidemic ... for giving his expert advice will be paid ?50,000 annually.// ... can mutate to spread rapidly among human beings. The exact ... revealed. The person appointed will dedicate himself solely to a ...
... created a non-invasive sensor that will help treat ... a patient faces respiratory distress in the emergency ... via a mask. But for some people with ... down the body's breathing reflex. , ,Spotting ...
... the US and Canada are looking to India to ... ,"Our consortium is trying to network to provide ... Remmers, a pioneer in the study of sleep disorder ... the consortium would include Christian Guilleminault, known as the ...
... the press that the drug Dasatinib has led to reduction ... , This drug is very effective in the ... previously used drug Gleevec. ,Chronic myeloid leukemia (CML) ... stage and the blast stage.,Dasatinib was tried on all these ...
... to enroll in treatment trials for lung cancer, according to ... of CANCER, the journal of the American Cancer Society.// ... a part of the chemotherapy regimen are primarily approved after ... well as researchers have stressed the need to enroll more ...
... Robarts Research Institute have found that supplementation of GSK-3 ... produce immune cells which fights against cancer cells.// Researchers ... in the treatment of Alzheimer’s and diabetes to boost ... effects. ,Cancer chemotherapy apart from being ...
Cached Medicine News:Health News:Cheap Indian devices sought to treat sleep disorder 2Health News:Wonder drug Dasatinib gives hopes to leukemia patients 2
... of six analyzer models providing a range of ... include pH, PCO 2 , PO 2 , ... calcium, chloride, glucose, and lactate. Test results are ... saving design provides the smallest footprint of any ...
... The modular design of Sleepscan VISION ... as economical upgrade opportunities. Sleepscan VISION utilizes ... to the computer through a standard Ethernet ... in the computer, allowing the Sleepscan VISION ...
... first 192 channel simultaneous sampling EEG with ... routine EEG exam rooms as well as ... Optional analysis software for automatic spike ... sleep analysis. Quality Data Acquisition ,The ...
... purchase an XLTEK Mobee, you're getting an ambulatory ... the Mobee32 and the Mobee O2 can be ... traditional in-lab EEG monitoring, or in-lab sleep studies. ... for full 10/20 electrode placement. The Mobee O2 ...
Medicine Products: